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WHATEVER HAPPENED TO THE POLYPILL?
Polypill is not just for cardiovascular disease
Fay H Cafferty senior statistician, Ruth E Langley professor of oncology and clinical trials
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials Methodology, Aviation House, London WC2B 6NH, UK
Viera’s article on the polypill focused exclusively on
cardiovascular benefits.1 Yet several candidates for inclusion
in such a formulation, such as aspirin and metformin, have
shown anticancer activity in recent years.
Randomised trials show that aspirin prevents the development
of colorectal cancer,2 3 and long term follow-up from vascular
trials indicates that aspirin inhibits development of metastases
in a range of cancers.4 This latter hypothesis is being evaluated
in several randomised trials,5 and metformin is being evaluated
as a treatment for both breast and prostate cancer.
In 2015, the US Preventive Services Task Force judged the
evidence sufficient to recommend daily low dose aspirin for
primary prevention of cardiovascular disease and colorectal
cancer in people aged 50-59 with a moderate risk of
cardiovascular disease and no increased risk of bleeding.6 This
approach factors in potential benefits (cardiovascular and cancer
outcomes), as well as age, which is associated with bleeding
risk.
Although aspirin increases bleeding risk, events are rarer than
generally appreciated: an estimated 3.6 additional serious
extracranial bleeding events (fatal or requiring transfusion) per
10 000 people treated for a year with aspirin. Intracranial
haemorrhage is rarer still (0.8 additional events).7
Instead of asking what happened to the polypill, perhaps we
should be asking how we can update our thinking about the
polypill. We agree that more evidence, including from the trials
mentioned, is needed before aspirin or a polypill containing
aspirin is recommended more widely. Evidence of anticancer
effects may shift the risk-benefit balance for some people. A
more individualised approach that assesses all possible benefits,
as well as risks, is likely to be appropriate and might help the
idea to slowly but surely gain ground.
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